Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 2

Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

,

Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.

EP. 1: The Current Treatment Landscape for R/R CLL
Now Viewing
EP. 2: Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
EP. 3: Key Patient-Specific Factors Guiding Treatment Selection in CLL
EP. 4: Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL
EP. 5: Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL
EP. 6: Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial
EP. 7: Application of Pirtobrutinib in R/R CLL: Expert Perspectives
EP. 8: Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL
EP. 9: Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors
EP. 10: Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL
EP. 11: Treatment Sequencing in Relapsed/Refractory CLL: Key Factors Influencing Decision-Making
EP. 12: Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives

Video content above is prompted by the following:

  • How does the prior line of therapy (BTKi vs BCL2i) influence your treatment decision?